JP2017502010A - 疼痛に対して多重モードの活性を有するピペリジン誘導体 - Google Patents

疼痛に対して多重モードの活性を有するピペリジン誘導体 Download PDF

Info

Publication number
JP2017502010A
JP2017502010A JP2016539899A JP2016539899A JP2017502010A JP 2017502010 A JP2017502010 A JP 2017502010A JP 2016539899 A JP2016539899 A JP 2016539899A JP 2016539899 A JP2016539899 A JP 2016539899A JP 2017502010 A JP2017502010 A JP 2017502010A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
methyl
piperidin
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016539899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502010A5 (enExample
Inventor
コルドベス，フェリックス クエバス
コルドベス，フェリックス クエバス
アルマンサ−ロサレス，カルメン
ロペス，モニカ ガルシア
ロペス，モニカ ガルシア
Original Assignee
ラボラトリオス・デル・デエレ・エステベ・エセ・ア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラボラトリオス・デル・デエレ・エステベ・エセ・ア filed Critical ラボラトリオス・デル・デエレ・エステベ・エセ・ア
Publication of JP2017502010A publication Critical patent/JP2017502010A/ja
Publication of JP2017502010A5 publication Critical patent/JP2017502010A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
JP2016539899A 2013-12-20 2014-12-19 疼痛に対して多重モードの活性を有するピペリジン誘導体 Ceased JP2017502010A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13384004.1 2013-12-20
EP13384004 2013-12-20
PCT/EP2014/078717 WO2015091939A1 (en) 2013-12-20 2014-12-19 Piperidine derivatives having multimodal activity against pain

Publications (2)

Publication Number Publication Date
JP2017502010A true JP2017502010A (ja) 2017-01-19
JP2017502010A5 JP2017502010A5 (enExample) 2018-02-01

Family

ID=49998040

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016539899A Ceased JP2017502010A (ja) 2013-12-20 2014-12-19 疼痛に対して多重モードの活性を有するピペリジン誘導体

Country Status (7)

Country Link
US (1) US9981942B2 (enExample)
EP (1) EP3083601B1 (enExample)
JP (1) JP2017502010A (enExample)
CN (1) CN105849096B (enExample)
CA (1) CA2931051A1 (enExample)
MX (1) MX2016006604A (enExample)
WO (1) WO2015091939A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019168164A1 (ja) * 2018-03-02 2019-09-06 国立大学法人大阪大学 タンパク質及び／又はペプチド修飾用分子

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018000419A (es) * 2015-07-29 2018-05-07 Esteve Labor Dr Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
MX2018000418A (es) 2015-07-29 2018-08-14 Esteve Labor Dr Derivados de amida que tienen actividad multimodal contra el dolor.
TW201808937A (zh) * 2016-05-20 2018-03-16 艾斯提夫博士實驗股份有限公司 針對疼痛具有多模態活性的四氫哌喃和噻喃衍生物
MX392422B (es) 2016-06-21 2025-03-24 Orion Ophthalmology LLC Derivados de prolinamida heterociclica
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
CN110392571B (zh) 2017-01-17 2023-07-04 梅比斯发现公司 取代的3-二烷基氨基甲基-哌啶-4-基-苯甲酰胺及其制备和使用方法
TW202304448A (zh) * 2021-04-07 2023-02-01 西班牙商塔拉森斯調節公司 作為西格瑪配位基的新（高）哌啶基雜環
EP4444305A2 (en) * 2022-02-16 2024-10-16 Duke Street Bio Limited Pharmaceutical compound
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004536104A (ja) * 2001-07-05 2004-12-02 シナプティック・ファーマスーティカル・コーポレーション Ｍｃｈ選択的アンタゴニストとしての置換されたアニリン−ピペリジン誘導体
JP2009502859A (ja) * 2005-07-29 2009-01-29 エフ．ホフマン−ラ ロシュ アーゲー インドール−３−イル−カルボニル−ピペリジン及びピペラジン誘導体
JP2009542809A (ja) * 2006-07-12 2009-12-03 メルク エンド カムパニー インコーポレーテッド グレリン受容体アンタゴニストとしての置換ピラゾール
WO2011041462A2 (en) * 2009-10-01 2011-04-07 Amira Pharmaceuticals, Inc. Polycyclic compounds as lysophosphatidic acid receptor antagonists

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL275537A (enExample) 1961-03-06
DE2109155A1 (en) 1971-02-26 1972-09-14 CH. Boehringer Sohn, 6507 Ingelheim 1-furylmethyl-4-phenyl-4-methoxycarbonylpiperidines - - with analgesic activity anorectic activity salt
GB9912410D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912411D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6727264B1 (en) * 2001-07-05 2004-04-27 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as MCH selective antagonists
US7381721B2 (en) * 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
MXPA06011827A (es) 2004-04-15 2007-01-16 Astellas Pharma Inc Derivado de 2-aminopirimidina.
US7645755B2 (en) * 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
CN101426774B (zh) * 2006-04-19 2012-04-25 安斯泰来制药有限公司 唑类甲酰胺衍生物
WO2008157844A1 (en) 2007-06-21 2008-12-24 Forest Laboratories Holdings Limited Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
WO2009029253A1 (en) 2007-08-27 2009-03-05 Theravance, Inc. Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
CA2704517A1 (en) * 2007-11-02 2009-05-07 Janssen Pharmaceutica, N.V. Use of cfms inhibitor for treating or preventing bone cancer and the bone loss and bone pain associated with bone cancer
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
WO2010080864A1 (en) 2009-01-12 2010-07-15 Array Biopharma Inc. Piperidine-containing compounds and use thereof
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
CA2931219A1 (en) 2013-12-20 2015-06-25 Laboratorios Del Dr. Esteve, S.A. Piperidine compounds having multimodal activity against pain

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004536104A (ja) * 2001-07-05 2004-12-02 シナプティック・ファーマスーティカル・コーポレーション Ｍｃｈ選択的アンタゴニストとしての置換されたアニリン−ピペリジン誘導体
JP2009502859A (ja) * 2005-07-29 2009-01-29 エフ．ホフマン−ラ ロシュ アーゲー インドール−３−イル−カルボニル−ピペリジン及びピペラジン誘導体
JP2009542809A (ja) * 2006-07-12 2009-12-03 メルク エンド カムパニー インコーポレーテッド グレリン受容体アンタゴニストとしての置換ピラゾール
WO2011041462A2 (en) * 2009-10-01 2011-04-07 Amira Pharmaceuticals, Inc. Polycyclic compounds as lysophosphatidic acid receptor antagonists

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019168164A1 (ja) * 2018-03-02 2019-09-06 国立大学法人大阪大学 タンパク質及び／又はペプチド修飾用分子
JPWO2019168164A1 (ja) * 2018-03-02 2021-01-14 国立大学法人大阪大学 タンパク質及び／又はペプチド修飾用分子
JP7013048B2 (ja) 2018-03-02 2022-01-31 国立大学法人大阪大学 タンパク質及び／又はペプチド修飾用分子

Also Published As

Publication number Publication date
CN105849096B (zh) 2019-11-29
EP3083601B1 (en) 2020-09-09
WO2015091939A1 (en) 2015-06-25
CN105849096A (zh) 2016-08-10
US9981942B2 (en) 2018-05-29
CA2931051A1 (en) 2015-06-25
US20170001978A1 (en) 2017-01-05
MX2016006604A (es) 2016-09-08
EP3083601A1 (en) 2016-10-26

Similar Documents

Publication Publication Date Title
JP2017502010A (ja) 疼痛に対して多重モードの活性を有するピペリジン誘導体
JP6553615B2 (ja) 疼痛に対して多重モードの活性を有するピペラジン誘導体
US10105359B2 (en) Tetrahydroisoquinoline derivatives
EP3149007B1 (en) Alkyl and aryl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
JP2018525363A (ja) 疼痛に対する多様な活性を有する置換アミド誘導体
CN110461838B (zh) 噁二唑瞬时受体电位通道抑制剂
CA2991572A1 (en) 6-amino-quinoline-3-carbonitrils as cot modulators
CN108349935B (zh) 吡咯烷衍生物
JPWO2014142221A1 (ja) 呼吸器疾患用薬
CA3085874A1 (en) Substituted pyrrolidine amides i
JPWO2015012400A1 (ja) グリシントランスポーター阻害物質
JP2016540793A (ja) 疼痛に対して多重モードの活性を有するピペリジン化合物
CN106255688B (zh) 吗啉-吡啶衍生物
TW202134213A (zh) 具有水解磷脂酸受體作動活性之化合物及其醫藥用途
JP2019516736A (ja) 疼痛に対する多様な活性を有するテトラヒドロピラン誘導体およびチオピラン誘導体
TWI680121B (zh) 具有抗疼痛之多重模式活性的哌𠯤衍生物
TW201627300A (zh) 具有抗疼痛之多重模式活性的哌啶衍生物
TW201627301A (zh) 具有抗疼痛之多重模式活性的哌啶化合物
HK40019933A (en) Pyridine derivatives
HK1228379B (zh) 吗啉-吡啶衍生物
NZ718251B2 (en) Piperazine derivatives and the use thereof as medicament

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200408

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200901

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20210119